Can Cancer Cure Pfizer?

Herper, Matthew
June 2008
Forbes Asia;6/2/2008, Vol. 4 Issue 10, p18
The article presents information on the pursuit of Pfizer Inc. to get cancer-fighting drugs out of its research labs into the market. The oncology drug market is forecasted to grow 50% to $85 billion by the year 2013. Pfizer has boosted antitumor research 60% since 2005 to $1.6 billion with its labs experimenting 18 potential medicines targeting pancreatic, breast and lung cancers.


Related Articles

  • Pfizer Abandons Heart Drug Development. Faloon, William // Life Extension;Nov2009, Vol. 15 Issue 11, p1 

    The article reports on the announcement given by Pfizer Inc., the largest drug company in the world, that it will no longer develop drugs that prevent or treat atherosclerotic heart disease. According to the company, they wanted to concentrate new drug research on more profitable areas like...

  • Investigator-initiated trials of targeted oncology agents: why independent research is at risk? Bergmann, L.; Berns, B.; Dalgleish, A. G.; von Euler, M.; Hecht, T. T.; Lappin, G. L.; Reed, N.; Palmeri, S.; Smyth, J.; Embacher-Aichorn, S.; Zwierzina, H. // Annals of Oncology;Aug2010, Vol. 21 Issue 8, p1573 

    Background: Drug development traditionally has relied upon the complementary contributions of clinicians and scientists at academic institutions and at pharmaceutical companies. Greater regulatory burdens, increased bureaucratic requirements, restricted reimbursement, and spiralling research and...

  • In This Issue.  // Clinical Pharmacology & Therapeutics;Sep2013, Vol. 94 Issue 3, p277 

    An introduction is presented in which the editor discusses various articles within the issue on topics including cancer drug development, therapeutic progress, and pharmaceutical innovation.

  • A Lifetime In Pharma. Jawadekar, Makarand // Contract Pharma;Jun2010, Vol. 12 Issue 5, p41 

    The article presents the authors' insights on his career in the pharmaceutical industry. He says that Pfizer Inc.'s Pharmaceutical R&D director Armando Aguiar gave him the opportunity to work in the company in which he had a 28-year tenure. He states that he worked on development projects...

  • What brand is that? Click to find out. Thomaselli, Rich // Advertising Age;4/10/2006, Vol. 77 Issue 15, p16 

    The article focuses on the efforts of the U.S. Food and Drug Administration and the Pharmaceutical Research and Manufacturers of America to push drug makers to produce more unbranded advertisements for prescription medications in 2006. For example, Pfizer's disease awareness campaign for...

  • Drug industry stumbles. Mirasol, Feliza // ICIS Chemical Business Americas;12/18/2006, Vol. 270 Issue 21, p34 

    This article focuses on the implications of the decision made by Pfizer to terminate its torcetrapib clinical trials for the pharmaceutical industry. The industry is concerned on its impact on the development of other cholesterol-lowering drugs. The termination of the clinical trial raises...

  • The role of industry. Prchla, Elisabeth // New Statesman;10/2/2015, Vol. 144 Issue 5282, p41 

    The article discusses the role of the pharmaceutical industry in cancer treatment in Great Britain. The author argues that the drug purchasing policies of Great Britain's Cancer Drugs Fund should be favorable to pharmaceutical firms despite high prices for some oncology medicines. Reforms to the...

  • SECTION 14 ONCOLOGY.  // MPR - Residents' Edition;Spring/Summer2011, Vol. 20 Issue 1, p168 

    The article offers brief information on various drugs for oncology including Alkeran for palliative treatment for multiple myeloma and non-resectable epithelial ovarian cancer from GlaxoSmithKline, Aromasin for estrogen-receptor positive early breast cancer from Pfizer Inc. and Avastin for...

  • Pfizer To Present New Research From Fifteen Compounds Highlighting Multiple Approaches To Targeting Cancer At 2011 ASCO Annual Meeting.  // Biomedical Market Newsletter;5/17/2011, p802 

    The article reports on the more than 30 abstracts to be presented by Pfizer Inc. for several investigational compounds at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois from June 3 to 7, 2011. It states that the presentation at ASCO reflects...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics